Inventor · disambiguated record
Francois Romagne
Also filed as: ROMAGNE FRANCOIS · ROMAGNE FRANÇOIS · ROMAGNÉ FRANCOIS · ROMAGNÉ FRANÇOIS
20 granted patents·17 pending applications·453 citations·filing 2003–2018
96Inventor score
Files withINNATE PHARMA SA10INNATE PHARMA9ROMAGNE FRANCOIS4MORETTA ALESSANDRO3NOVO NORDISK AS NOVO ALLE3
Top patents by PatentIndex Score
37 records- 0197US9717803B2Enzymatic conjugation of polypeptidesINNATE PHARMA·Filed 2012·Granted Aug 1, 2017·29 cites·40 claims
- 0296US10675359B2Enzymatic conjugation of antibodiesINNATE PHARMA·Filed 2017·Granted Jun 9, 2020·11 cites·24 claims
- 0396US9764038B2Enzymatic conjugation of antibodiesINNATE PHARMA·Filed 2012·Granted Sep 19, 2017·38 cites·13 claims
- 0495US9067997B2Anti-KIR antibodies for the treatment of inflammatory and autoimmune disordersROMAGNE FRANCOIS·Filed 2012·Granted Jun 30, 2015·40 cites·35 claims
- 0595US8119775B2Human anti-KIR antibodiesMORETTA ALESSANDRO·Filed 2008·Granted Feb 21, 2012·68 cites·20 claims
- 0694US10434180B2Enzymatic conjugation of polypeptidesINNATE PHARMA·Filed 2016·Granted Oct 8, 2019·20 cites·13 claims
- 0794US9427478B2Enzymatic conjugation of polypeptidesINNATE PHARMA·Filed 2014·Granted Aug 30, 2016·30 cites·21 claims
- 0893US9447185B2Compositions and methods for treating proliferative disordersROMAGNE FRANCOIS·Filed 2006·Granted Sep 20, 2016·46 cites·6 claims
- 0993US8993319B2Monoclonal antibodies against NKG2AMORETTA ALESSANDRO·Filed 2005·Granted Mar 31, 2015·31 cites·1 claims
- 1092US10160810B2Monoclonal antibodies against NKG2AINNATE PHARMA SA·Filed 2015·Granted Dec 25, 2018·14 cites·5 claims
- 1191US10059765B2Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compoundsINNATE PHARMA SA·Filed 2015·Granted Aug 28, 2018·15 cites·23 claims
- 1291US8981065B2Human anti-KIR antibodiesNOVO NORDISK AS —NOVO ALLE·Filed 2013·Granted Mar 17, 2015·25 cites·18 claims
- 1389US8614307B2Nucleic acids encoding human anti-kir antibodiesMORETTA ALESSANDRO·Filed 2012·Granted Dec 24, 2013·15 cites·13 claims
- 1488US9090876B2Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compoundsVELARDI ANDREA·Filed 2010·Granted Jul 28, 2015·20 cites·58 claims
- 1586US7803376B2Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compoundsINNATE PHARMA SA·Filed 2004·Granted Sep 28, 2010·24 cites·24 claims
- 1683US10036010B2Recognition tags for TGase-mediated conjugationINNATE PHARMA·Filed 2013·Granted Jul 31, 2018·4 cites·8 claims
- 1782US8551483B2Methods of treating viral infections by administering KIR2DL-binding antibodiesWAGTMANN PETER ANDREAS NICOLAI REUMERT·Filed 2006·Granted Oct 8, 2013·11 cites·7 claims
- 1881US10253095B2Anti-KIR combination treatments and methodsROMAGNE FRANCOIS·Filed 2011·Granted Apr 9, 2019·6 cites·7 claims
- 1978US10132799B2Screening of conjugated antibodiesINNATE PHARMA·Filed 2013·Granted Nov 20, 2018·3 cites·22 claims
- 2071US9333255B2Methods of enhancing antibody-based antiviral therapies by administering KIR2DL-binding antibodiesNOVO NORKISK AS·Filed 2013·Granted May 10, 2016·3 cites·12 claims
- 2160US2019135938A1Monoclonal antibodies against nkg2aINNATE PHARMA SA·Filed 2018·Application pending·0 cites
- 2257US2018071402A1Enzymatic conjugation of polypeptidesINNATE PHARMA·Filed 2017·Application pending·0 cites
- 2357US2019169601A1Recognition tags for tgase-mediated conjugationINNATE PHARMA·Filed 2018·Application pending·0 cites
- 2451US2015344576A1Human anti-kir antibodiesNOVO NORDISK AS NOVO ALLE·Filed 2015·Application pending·0 cites
- 2551US2011229486A1Monoclonal Antibodies Against NKG2AINNATE PHARMA SA·Filed 2011·Application pending·0 cites
- 2649US2009196850A1Anti-Kir Combination Treatments and MethodsNOVO NORDISK AS·Filed 2006·Application pending·0 cites
- 2749US2015191547A1Human anti-kir antibodiesNOVO NORDISK AS NOVO ALLE·Filed 2015·Application pending·0 cites
- 2848US2006194755A1Compositions and methods for regulating an immune response in a subjectINNATE PHARMA SAS·Filed 2003·Application pending·0 cites
- 2947US2007134273A1Composition and method for the treatment of carcinomaROMAGNE FRANCOIS·Filed 2005·Application pending·0 cites
- 3045US2008196112A1Transgenic Animals and Methods of Making Recombinant AntibodiesINNATE PHARMA SA·Filed 2006·Application pending·0 cites
- 3144US2008063717A1Pharmaceutical Compositions Having an Effect on the Proliferation of Nk Cells and a Method Using the SameINNATE PHARMA SAS·Filed 2003·Application pending·0 cites
- 3243US2005196385A1Methods for producing gamma delta t cellsINNATE PHARAMA·Filed 2003·Application pending·0 cites
- 3342US2015376275A1Anti-kir antibodies for the treatment of inflammatory and autoimmune disordersINNATE PHARMA SA·Filed 2015·Application pending·0 cites
- 3442US2010254940A1Compositions and Methods for Regulating an Immune Response in a SubjectINNATE PHARMA SA·Filed 2010·Application pending·0 cites
- 3542US2007178106A1Compositions and methods for enhancing nk cell activityINNATE PHARMA SA·Filed 2005·Application pending·0 cites
- 3641US2011185441A1Transgenic animals and methods of making recombinant antibodiesINNATE PHARMA SA·Filed 2011·Application pending·0 cites
- 3741US2007231322A1Compositions and Methods for Treating Proliferative Disorders Such as Nk-Type LdglUNIV GENOVA·Filed 2005·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →